The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis

References

• Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358(13):1370–1380.
   PubMed Web of Science ®Google Scholar
• Pathak A, Del monte F, Zhao W, et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res. 2005;96(7):756–766.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450–1488.
   PubMed Web of Science ®Google Scholar
• Carrizales-Sepúlveda EF, Ordaz-Farías A, Vera-Pineda R, Flores-Ramírez R. Periodontal Disease, Systemic Inflammation and the Risk of Cardiovascular Disease. Heart Lung Circ. 2018;27(11):1327–1334.
   PubMed Web of Science ®Google Scholar
• Anzai T. Inflammatory Mechanisms of Cardiovascular Remodeling. Circ J. 2018;82(3):629–635.
   PubMed Web of Science ®Google Scholar
• Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13(2):148–159.
   PubMed Web of Science ®Google Scholar
• Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240–273.
   PubMed Web of Science ®Google Scholar
• Burdette BE, Esparza AN, Zhu H, Wang S. Gasdermin D in pyroptosis. Acta Pharm Sin B. 2021;11(9):2768–2782.
   PubMed Web of Science ®Google Scholar
• Rathinam VAK, Zhao Y, Shao F. Innate immunity to intracellular LPS. Nat Immunol. 2019;20(5):527–533.
   PubMed Web of Science ®Google Scholar
• Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505–522.
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: an Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20:13.
   Web of Science ®Google Scholar
• Wang Q, Wu J, Zeng Y, et al. Pyroptosis: a pro-inflammatory type of cell death in cardiovascular disease. Clin Chim Acta. 2020;510:62–72.
   PubMed Web of Science ®Google Scholar
• Yang CS, Shin DM, Jo EK. The Role of NLR-related Protein 3 Inflammasome in Host Defense and Inflammatory Diseases. Int Neurourol J. 2012;16(1):2–12.
   PubMed Web of Science ®Google Scholar
• Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407–420.
   PubMed Web of Science ®Google Scholar
• Kanneganti TD, Lamkanfi M, Núñez G. Intracellular NOD-like receptors in host defense and disease. Immunity. 2007;27(4):549–559.
   PubMed Web of Science ®Google Scholar
• Fidler TP, Xue C, Yalcinkaya M, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021;592(7853):296–301.
   PubMed Web of Science ®Google Scholar
• Sharma D, Kanneganti TD. The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation. J Cell Biol. 2016;213(6):617–629.
   PubMed Web of Science ®Google Scholar
• Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature. 2014;513(7517):237–241.
   PubMed Web of Science ®Google Scholar
• Zhen Y, Zhang H. NLRP3 Inflammasome and Inflammatory Bowel Disease. Front Immunol. 2019;10:276.
   PubMed Web of Science ®Google Scholar
• Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397–411.
   PubMed Web of Science ®Google Scholar
• Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733.
   PubMed Web of Science ®Google Scholar
• Cornut M, Bourdonnay E, Henry T. Transcriptional Regulation of Inflammasomes. Int J Mol Sci. 2020;21(21):849.
   PubMed Web of Science ®Google Scholar
• Toldo S, Mezzaroma E, McGeough MD, et al. Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. Cardiovasc Res. 2015;105(2):203–212.
   PubMed Web of Science ®Google Scholar
• El-Sharkawy LY, Brough D, Freeman S. Inhibiting the NLRP3 Inflammasome. Molecules. 2020;25(23):548.
   PubMed Web of Science ®Google Scholar
• Shokoples BG, Paradis P, Schiffrin EL. P2X7 Receptors: an Untapped Target for the Management of Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2021;41(1):186–199.
   PubMed Web of Science ®Google Scholar
• Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011;22(4):189–195.
   PubMed Web of Science ®Google Scholar
• Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221–225.
   PubMed Web of Science ®Google Scholar
• Bracey NA, Gershkovich B, Chun J, et al. Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome. J Biol Chem. 2014;289(28):19571–19584.
   PubMed Web of Science ®Google Scholar
• Chung C, Seo W, Silwal P, Jo EK. Crosstalks between inflammasome and autophagy in cancer. J Hematol Oncol. 2020;13(1):100.
   PubMed Web of Science ®Google Scholar
• Muñoz-Planillo R, Kuffa P, Martínez-Colón G, Smith BL, Rajendiran TM, Núñez G. K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38(6):1142–1153.
   PubMed Web of Science ®Google Scholar
• Mathur A, Hayward JA, Man SM. Molecular mechanisms of inflammasome signaling. J Leukoc Biol. 2018;103(2):233–257.
   PubMed Web of Science ®Google Scholar
• Liu G, Chen X, Wang Q, Yuan L. NEK7: a potential therapy target for NLRP3-related diseases. Biosci Trends. 2020;14(2):74–82.
   PubMed Web of Science ®Google Scholar
• He Y, Zeng MY, Yang D, Motro B, Núñez G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature. 2016;530(7590):354–357.
   PubMed Web of Science ®Google Scholar
• Tao Y, Yang Y, Zhou R, Gong T. Golgi Apparatus: an Emerging Platform for Innate Immunity. Trends Cell Biol. 2020;30(6):467–477.
   PubMed Web of Science ®Google Scholar
• Hong S, Hwang I, Gim E, et al. Brefeldin A-sensitive ER-Golgi vesicle trafficking contributes to NLRP3-dependent caspase-1 activation. FASEB j. 2019;33(3):4547–4558.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu X, Shi H, et al. NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases. Clin Transl Med. 2020;10(1):91–106.
   PubMed Web of Science ®Google Scholar
• Guo C, Chi Z, Jiang D, et al. Cholesterol Homeostatic Regulator SCAP-SREBP2 Integrates NLRP3 Inflammasome Activation and Cholesterol Biosynthetic Signaling in Macrophages. Immunity. 2018;49(5):842–856.e847.
   PubMed Web of Science ®Google Scholar
• Gong T, Jiang W, Zhou R. Control of Inflammasome Activation by Phosphorylation. Trends Biochem Sci. 2018;43(9):685–699.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019;65:70–99.
   PubMed Web of Science ®Google Scholar
• Park S, Nguyen NB, Pezhouman A, Ardehali R. Cardiac fibrosis: potential therapeutic targets. Transl Res. 2019;209:121–137.
   PubMed Web of Science ®Google Scholar
• Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009;123(2):255–278.
   PubMed Web of Science ®Google Scholar
• Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res. 2005;65(1):40–51.
   PubMed Web of Science ®Google Scholar
• Tallquist MD. Cardiac Fibroblast Diversity. Annu Rev Physiol. 2020;82:63–78.
   PubMed Web of Science ®Google Scholar
• Liu M, López de Juan Abad B, Cheng K. Cardiac fibrosis: myofibroblast-mediated pathological regulation and drug delivery strategies. Adv Drug Deliv Rev. 2021;173:504–519.
   PubMed Web of Science ®Google Scholar
• Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71(4):549–574.
   PubMed Web of Science ®Google Scholar
• Khalil H, Kanisicak O, Prasad V, et al. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest. 2017;127(10):3770–3783.
   PubMed Web of Science ®Google Scholar
• Baci D, Bosi A, Parisi L, et al. Innate Immunity Effector Cells as Inflammatory Drivers of Cardiac Fibrosis. Int J Mol Sci. 2020;21:19.
   Web of Science ®Google Scholar
• Sandanger Ø, Gao E, Ranheim T, et al. NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective. Biochem Biophys Res Commun. 2016;469(4):1012–1020.
   PubMed Web of Science ®Google Scholar
• Pinar AA, Scott TE, Huuskes BM, Tapia Cáceres FE, Kemp-Harper BK, Samuel CS. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacol Ther. 2020;209:107511.
   PubMed Web of Science ®Google Scholar
• Louwe MC, Olsen MB, Kaasbøll OJ, et al. Absence of NLRP3 Inflammasome in Hematopoietic Cells Reduces Adverse Remodeling After Experimental Myocardial Infarction. JACC Basic Transl Sci. 2020;5(12):1210–1224.
   PubMedGoogle Scholar
• Díaz-Araya G, Vivar R, Humeres C, Boza P, Bolivar S, Muñoz C. Cardiac fibroblasts as sentinel cells in cardiac tissue: receptors, signaling pathways and cellular functions. Pharmacol Res. 2015;101:30–40.
   PubMed Web of Science ®Google Scholar
• Cáceres FT, Gaspari TA, Samuel CS, Pinar AA. Serelaxin inhibits the profibrotic TGF-β1/IL-1β axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts. FASEB j. 2019;33(12):14717–14733.
   PubMed Web of Science ®Google Scholar
• Wu D, Chen Y, Sun Y, et al. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review. Inflammation. 2020;43(1):17–23.
   PubMed Web of Science ®Google Scholar
• Gao R, Shi H, Chang S, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int Immunopharmacol. 2019;74:105575.
   PubMed Web of Science ®Google Scholar
• Gan W, Ren J, Li T, et al. The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864(1):1–10.
   PubMed Web of Science ®Google Scholar
• Lv SL, Zeng ZF, Gan WQ, et al. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation. Acta Pharmacol Sin. 2021;42(12):2016–2032.
   PubMed Web of Science ®Google Scholar
• Pan XC, Liu Y, Cen YY, et al. Dual Role of Triptolide in Interrupting the NLRP3 Inflammasome Pathway to Attenuate Cardiac Fibrosis. Int J Mol Sci. 2019;20(2):849.
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123(6):594–604.
   PubMed Web of Science ®Google Scholar
• Lu A, Magupalli VG, Ruan J, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell. 2014;156(6):1193–1206.
   PubMed Web of Science ®Google Scholar
• Sandanger Ø, Ranheim T, Vinge LE, et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2013;99(1):164–174.
   PubMed Web of Science ®Google Scholar
• Qin L, Zang M, Xu Y, et al. Chlorogenic Acid Alleviates Hyperglycemia-Induced Cardiac Fibrosis through Activation of the NO/cGMP/PKG Pathway in Cardiac Fibroblasts. Mol Nutr Food Res. 2021;65(2):e2000810.
   PubMed Web of Science ®Google Scholar
• Luo B, Li B, Wang W, et al. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther. 2014;28(1):33–43.
   PubMed Web of Science ®Google Scholar
• Yue Y, Meng K, Pu Y, Zhang X. Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract. 2017;133:124–130.
   PubMed Web of Science ®Google Scholar
• Nie C, Zou R, Pan S, et al. Hydrogen gas inhalation ameliorates cardiac remodelling and fibrosis by regulating NLRP3 inflammasome in myocardial infarction rats. J Cell Mol Med. 2021;25(18):8997–9010.
   PubMed Web of Science ®Google Scholar
• Sharma A, Tate M, Mathew G, Vince JE, Ritchie RH, de Haan JB. Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: therapeutic Implications. Front Physiol. 2018;9:114.
   PubMed Web of Science ®Google Scholar
• Wang BF, Yoshioka J. The Emerging Role of Thioredoxin-Interacting Protein in Myocardial Ischemia/Reperfusion Injury. J Cardiovasc Pharmacol Ther. 2017;22(3):219–229.
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen X, Zong B, et al. Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation. J Cell Mol Med. 2018;22(9):4437–4448.
   PubMed Web of Science ®Google Scholar
• Che H, Wang Y, Li H, et al. Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy. FASEB j. 2020;34(4):5282–5298.
   PubMed Web of Science ®Google Scholar
• Li S, Li Z, Yin R, Nie J, Fu Y, Ying R. Knockdown of dual oxidase 1 suppresses activin A-induced fibrosis in cardiomyocytes via the reactive oxygen species-dependent pyroptotic pathway. Int J Biochem Cell Biol. 2021;131:105902.
   PubMed Web of Science ®Google Scholar
• Zhang X, Fu Y, Li H, et al. H3 relaxin inhibits the collagen synthesis via ROS- and P2X7R-mediated NLRP3 inflammasome activation in cardiac fibroblasts under high glucose. J Cell Mol Med. 2018;22(3):1816–1825.
   PubMed Web of Science ®Google Scholar
• Yao J, Li Y, Jin Y, Chen Y, Tian L, He W. Synergistic cardioptotection by tilianin and syringin in diabetic cardiomyopathy involves interaction of TLR4/NF-κB/NLRP3 and PGC1a/SIRT3 pathways. Int Immunopharmacol. 2021;96:107728.
   PubMed Web of Science ®Google Scholar
• Baman JR, Passman RS. Atrial Fibrillation. JAMA. 2021;325(21):2218.
   PubMed Web of Science ®Google Scholar
• Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230–243.
   PubMed Web of Science ®Google Scholar
• Ihara K, Sasano T. Role of Inflammation in the Pathogenesis of Atrial Fibrillation. Front Physiol. 2022;13:862164.
   PubMed Web of Science ®Google Scholar
• Qiu H, Liu W, Lan T, et al. Salvianolate reduces atrial fibrillation through suppressing atrial interstitial fibrosis by inhibiting TGF-β1/Smad2/3 and TXNIP/NLRP3 inflammasome signaling pathways in post-MI rats. Phytomedicine. 2018;51:255–265.
   PubMed Web of Science ®Google Scholar
• Yao C, Veleva T, Scott L, et al. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018;138(20):2227–2242.
   PubMed Web of Science ®Google Scholar
• Cheng T, Wang XF, Hou YT, Zhang L. Correlation between atrial fibrillation, serum amyloid protein A and other inflammatory cytokines. Mol Med Rep. 2012;6(3):581–584.
   PubMed Web of Science ®Google Scholar
• Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: a Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984–e1010.
   PubMed Web of Science ®Google Scholar
• Sala L, Pontiroli AE. Role of obesity and hypertension in the incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes. Cardiovasc Diabetol. 2021;20(1):162.
   PubMed Web of Science ®Google Scholar
• Scott L, Fender AC, Saljic A, et al. NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias. Cardiovasc Res. 2021;117(7):1746–1759.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728–741.
   PubMed Web of Science ®Google Scholar
• Li L, Tan J, Miao Y, Lei P, Zhang Q. ROS and Autophagy: interactions and Molecular Regulatory Mechanisms. Cell Mol Neurobiol. 2015;35(5):615–621.
   PubMed Web of Science ®Google Scholar
• Liu PP, Liu HH, Sun SH, et al. Aspirin alleviates cardiac fibrosis in mice by inhibiting autophagy. Acta Pharmacol Sin. 2017;38(4):488–497.
   PubMed Web of Science ®Google Scholar
• Kovacs SB, Miao EA. Gasdermins: effectors of Pyroptosis. Trends Cell Biol. 2017;27(9):673–684.
   PubMed Web of Science ®Google Scholar
• Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6(1):128.
   PubMed Web of Science ®Google Scholar
• Miao EA, Leaf IA, Treuting PM, et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol. 2010;11(12):1136–1142.
   PubMed Web of Science ®Google Scholar
• Baker PJ, Boucher D, Bierschenk D, et al. NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. Eur J Immunol. 2015;45(10):2918–2926.
   PubMed Web of Science ®Google Scholar
• Zhang X, Hu C, Yuan YP, et al. Endothelial ERG alleviates cardiac fibrosis via blocking endothelin-1-dependent paracrine mechanism. Cell Biol Toxicol. 2021;37(6):873–890.
   PubMed Web of Science ®Google Scholar
• Jia C, Chen H, Zhang J, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 2019;67:311–318.
   PubMed Web of Science ®Google Scholar
• Prabhu SD, Frangogiannis NG. The Biological Basis for Cardiac Repair After Myocardial Infarction: from Inflammation to Fibrosis. Circ Res. 2016;119(1):91–112.
   PubMed Web of Science ®Google Scholar
• Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563–581.
   PubMed Web of Science ®Google Scholar
• Luo B, Li B, Wang W, et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One. 2014;9(8):e104771.
   PubMed Web of Science ®Google Scholar
• Mastrocola R, Penna C, Tullio F, et al. Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways. Oxid Med Cell Longev. 2016;2016:5271251.
   PubMed Web of Science ®Google Scholar
• Gao RF, Li X, Xiang HY, et al. The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice. Int Immunopharmacol. 2021;90:107133.
   PubMed Web of Science ®Google Scholar
• Toldo S, Mauro AG, Cutter Z, et al. The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse. J Cardiovasc Pharmacol. 2019;73(4):215–222.
   PubMed Web of Science ®Google Scholar
• Chen S, Wang Y, Pan Y, et al. Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis. J Am Heart Assoc. 2020;9(12):e015513.
   PubMed Web of Science ®Google Scholar
• See F, Watanabe M, Kompa AR, et al. Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction. Heart Lung Circ. 2013;22(2):122–132.
   PubMed Web of Science ®Google Scholar
• Kelly DJ, Zhang Y, Connelly K, et al. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2007;293(5):H2860–2869.
   PubMed Web of Science ®Google Scholar
• Huang Y, Jiang H, Chen Y, et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. 2018;10:4.
   PubMed Web of Science ®Google Scholar
• Ohta S. Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine. Pharmacol Ther. 2014;144(1):1–11.
   PubMed Web of Science ®Google Scholar
• Nie C, Ding X. Hydrogen gas inhalation alleviates myocardial ischemia-reperfusion injury by the inhibition of oxidative stress and NLRP3-mediated pyroptosis in rats. Life Sci. 2021;272:119248.
   PubMed Web of Science ®Google Scholar
• Kang LL, Zhang DM, Ma CH, et al. Cinnamaldehyde and allopurinol reduce fructose-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4/6-IRAK4/1 signaling to suppress NLRP3 inflammasome activation. Sci Rep. 2016;6:27460.
   PubMed Web of Science ®Google Scholar
• Pascart T, Richette P. Colchicine in Gout: an Update. Curr Pharm Des. 2018;24(6):684–689.
   PubMed Web of Science ®Google Scholar
• Leung YY, Yao Hui LL, Kraus VB. Colchicine–Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341–350.
   PubMed Web of Science ®Google Scholar
• Fujisue K, Sugamura K, Kurokawa H, et al. Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction. Circ J. 2017;81(8):1174–1182.
   PubMed Web of Science ®Google Scholar
• Marques-da-Silva C, Chaves MM, Castro NG, Coutinho-Silva R, Guimaraes MZ. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol. 2011;163(5):912–926.
   PubMed Web of Science ®Google Scholar
• Ge C, Cheng Y, Fan Y, He Y. Vincristine attenuates cardiac fibrosis through the inhibition of NLRP3 inflammasome activation. Clin Sci (Lond). 2021;135(11):1409–1426.
   PubMed Web of Science ®Google Scholar
• Yue R, Zheng Z, Luo Y, et al. NLRP3-mediated pyroptosis aggravates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction in mice: cardioprotective role of irisin. Cell Death Discov. 2021;7(1):50.
   PubMed Web of Science ®Google Scholar
• Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003;11(10):738–746.
   PubMed Web of Science ®Google Scholar
• Wannamaker W, Davies R, Namchuk M, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321(2):509–516.
   PubMed Web of Science ®Google Scholar
• Ku GFP, Raybuck S, Harding M, Randle J. Selective Interleukin-1β Converting Enzyme (ICE/Caspase-1) Inhibition with Pralnacasan (HMR 3480/VX-740) Reduces Inflammation and Joint Destruction in Murine Type II Collagen-Induced Arthritis (CIA). Arthritis Rheumatism. 2001;44(9):S241.
   PubMedGoogle Scholar
• Audia JP, Yang XM, Crockett ES, et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y(12) receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol. 2018;113(5):32.
   PubMed Web of Science ®Google Scholar
• Kudelova J, Fleischmannova J, Adamova E, Matalova E. Pharmacological caspase inhibitors: research towards therapeutic perspectives. J Physiol Pharmacol. 2015;66(4):473–482.
   PubMed Web of Science ®Google Scholar
• Hisahara S, Takano R, Shoji S, Okano H, Miura M. Role of caspase-1 subfamily in cytotoxic cytokine-induced oligodendrocyte cell death. J Neural Transm Suppl. 2000;1(58):135–142.
   Google Scholar
• Lu B, Xie J, Fu D, et al. Huoxue Qianyang Qutan recipe attenuates cardiac fibrosis by inhibiting the NLRP3 inflammasome signalling pathway in obese hypertensive rats. Pharm Biol. 2021;59(1):1045–1057.
   PubMed Web of Science ®Google Scholar
• Pfeiler S, Winkels H, Kelm M, Gerdes N. IL-1 family cytokines in cardiovascular disease. Cytokine. 2019;122:154215.
   PubMed Web of Science ®Google Scholar
• Dhimolea E. Canakinumab. MAbs. 2010;2(1):3–13.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Ramírez J, Cañete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018;17(7):727–732.
   PubMed Web of Science ®Google Scholar
• Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still’s disease. Rheumatology. 2019;58(Suppl6):vi9–vi22.
   PubMed Web of Science ®Google Scholar
• Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331.
   PubMedGoogle Scholar
• Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593.
   PubMed Web of Science ®Google Scholar
• Yang F, Qin Y, Wang Y, et al. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. Int J Biol Sci. 2019;15(5):1010–1019.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Muscelli E, Astiarraga B, Barsotti E, et al. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes. Diabetologia. 2016;59(4):700–708.
   PubMed Web of Science ®Google Scholar
• Byrne NJ, Matsumura N, Maayah ZH, et al. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. Circ Heart Fail. 2020;13(1):e006277.
   PubMed Web of Science ®Google Scholar
• Li JX, Shi JF, Wu YH, Xu HT, Fu CM, Zhang JM. [Mechanisms and application of triptolide against breast cancer]. Zhongguo Zhong Yao Za Zhi. 2021;46(13):3249–3256. Chinese.
   PubMedGoogle Scholar
• Cai J, Yi M, Tan Y, et al. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J Exp Clin Cancer Res. 2021;40(1):190.
   PubMed Web of Science ®Google Scholar
• Zhou X, Lu B, Fu D, Gui M, Yao L, Li J. Huoxue Qianyang decoction ameliorates cardiac remodeling in obese spontaneously hypertensive rats in association with ATF6-CHOP endoplasmic reticulum stress signaling pathway regulation. Biomed Pharmacother. 2020;121:109518.
   PubMed Web of Science ®Google Scholar
• Semwal RB, Semwal DK, Combrinck S, Viljoen A. Emodin - A natural anthraquinone derivative with diverse pharmacological activities. Phytochemistry. 2021;190:112854.
   PubMed Web of Science ®Google Scholar
• Dai S, Ye B, Chen L, Hong G, Zhao G, Lu Z. Emodin alleviates LPS-induced myocardial injury through inhibition of NLRP3 inflammasome activation. Phytother Res. 2021;35(9):5203–5213.
   PubMed Web of Science ®Google Scholar